Predictive Factors of Early Response to Dupilumab in Patients with Moderate-to-Severe Atopic Dermatitis

被引：4

作者：

Ferrucci, Silvia ^{[1
]}

Casazza, Giovanni ^{[2
]}

Zussino, Martina ^{[1
]}

Tavecchio, Simona ^{[3
]}

Marzano, Angelo V. ^{[1
,3
]}

Tedeschi, Micol ^{[1
,4
]}

机构：

[1] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Dermatol Unit, I-20122 Milan, Italy

[2] Univ Milan, Dept Clin Sci & Community Hlth, I-20122 Milan, Italy

[3] Univ Milan, Dept Pathophysiol & Transplantat, I-20122 Milan, Italy

[4] Univ Pavia, Dept Clin Surg Diagnost & Pediat Sci, Pediat Unit, I-27100 Pavia, Italy

来源：

JOURNAL OF CLINICAL MEDICINE | 2023年 / 12卷 / 20期

关键词：

atopic dermatitis; dupilumab; early reposnders; PLACEBO; ECZEMA; RELIABILITY; BARRIER; ADULTS;

D O I：

10.3390/jcm12206575

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Efforts have been made to identify factors influencing clinical response in patients with atopic dermatitis (AD) treated with dupilumab. A retrospective single-center observational study was carried out by analyzing data from 492 patients aged 12 years and older with moderate-to-severe AD. The study aimed to identify baseline demographic and clinical factors that could predict the achievement of a mild level of disease, i.e., an Eczema Area and Severity Index (EASI) <= 7, within 4 weeks from dupilumab initiation. Classic, generalized lichenoid and inflammatory phenotypes compared with a nummular eczema phenotype (OR = 6.9, 95% CI 2.04-23.48 and OR = 4.22, 95% CI 1.22-14.66, respectively) and a baseline EASI <= 24 and between 24-29, compared with a baseline EASI >= 29 (OR = 3.1, 95% CI 1.81-5.41 and OR = 1.8, 95% CI 1.05-3.07, respectively), were found to be predictive factors of early response to dupilumab, highlighting the importance of early biological treatment of AD.

引用

页数：11

共 36 条

[1] Does the epithelial barrier hypothesis explain the increase in allergy, autoimmunity and other chronic conditions? [J].

Akdis, Cezmi A. .

NATURE REVIEWS IMMUNOLOGY, 2021, 21 (11) :739-751

[2] Conjunctivitis in dupilumab clinical trials [J].

Akinlade, B. ;

Guttman-Yassky, E. ;

de Bruin-Weller, M. ;

Simpson, E. L. ;

Blauvelt, A. ;

Cork, M. J. ;

Prens, E. ;

Asbell, P. ;

Akpek, E. ;

Corren, J. ;

Bachert, C. ;

Hirano, I. ;

Weyne, J. ;

Korotzer, A. ;

Chen, Z. ;

Hultsch, T. ;

Zhu, X. ;

Davis, J. D. ;

Mannent, L. ;

Hamilton, J. D. ;

Teper, A. ;

Staudinger, H. ;

Rizova, E. ;

Pirozzi, G. ;

Graham, N. M. H. ;

Shumel, B. ;

Ardeleanu, M. ;

Wollenberg, A. .

BRITISH JOURNAL OF DERMATOLOGY, 2019, 181 (03) :459-473

[3]

[Anonymous], 1946, PUBLIC HEALTH REP, V61, P1268

[4]

Badia X, 1999, BRIT J DERMATOL, V141, P698

[5] Dupilumab Provides Acceptable Safety and Sustained Efficacy for up to 4 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis [J].

Beck, Lisa A. ;

Deleuran, Mette ;

Bissonnette, Robert ;

de Bruin-Weller, Marjolein ;

Galus, Ryszard ;

Nakahara, Takeshi ;

Seo, Seong Jun ;

Khokhar, Faisal A. ;

Vakil, Jignesh ;

Xiao, Jing ;

Marco, Ainara Rodriguez ;

Levit, Noah A. ;

O'Malley, John T. ;

Shabbir, Arsalan .

AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 2022, 23 (03) :393-408

[6] Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial [J].

Blauvelt, Andrew ;

de Bruin-Weller, Marjolein ;

Gooderham, Melinda ;

Cather, Jennifer C. ;

Weisman, Jamie ;

Pariser, David ;

Simpson, Eric L. ;

Papp, Kim A. ;

Hong, H. Chih-Ho ;

Rubel, Diana ;

Foley, Peter ;

Prens, Errol ;

Griffiths, Christopher E. M. ;

Etoh, Takafumi ;

Pinto, Pedro Herranz ;

Pujol, Ramon M. ;

Szepietowski, Jacek C. ;

Ettler, Karel ;

Kemeny, Lajos ;

Zhu, Xiaoping ;

Akinlade, Bolanle ;

Hultsch, Thomas ;

Mastey, Vera ;

Gadkari, Abhijit ;

Eckert, Laurent ;

Amin, Nikhil ;

Graham, Neil M. H. ;

Pirozzi, Gianluca ;

Stahl, Neil ;

Yancopoulos, George D. ;

Shumel, Brad .

LANCET, 2017, 389 (10086) :2287-2303

[7] A systematic review of the safety of topical therapies for atopic dermatitis [J].

Callen, J. ;

Chamlin, S. ;

Eichenfield, L. F. ;

Ellis, C. ;

Girardi, M. ;

Goldfarb, M. ;

Hanifin, J. ;

Lee, P. ;

Margolis, D. ;

Paller, A. S. ;

Piacquadio, D. ;

Peterson, W. ;

Kaulback, K. ;

Fennerty, M. ;

Wintroub, B. U. .

BRITISH JOURNAL OF DERMATOLOGY, 2007, 156 (02) :203-221

[8] The evolving landscape of biologic therapies for atopic dermatitis: Present and future perspective [J].

David, Eden ;

Ungar, Benjamin ;

Renert-Yuval, Yael ;

Facheris, Paola ;

del Duca, Ester ;

Guttman-Yassky, Emma .

CLINICAL AND EXPERIMENTAL ALLERGY, 2023, 53 (02) :156-172

[9] Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAFE) [J].

de Bruin-Weller, M. ;

Thaci, D. ;

Smith, C. H. ;

Reich, K. ;

Cork, M. J. ;

Radin, A. ;

Zhang, Q. ;

Akinlade, B. ;

Gadkari, A. ;

Eckert, L. ;

Hultsch, T. ;

Chen, Z. ;

Pirozzi, G. ;

Graham, N. M. H. ;

Shumel, B. .

BRITISH JOURNAL OF DERMATOLOGY, 2018, 178 (05) :1083-1101

[10]

Dupilumab, AIFA Summary of Product Characteristics

← 1 2 3 4 →